Related references
Note: Only part of the references are listed.Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population
D. Castellano et al.
ANNALS OF ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: Results from a phase III randomized trial
David Cella et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Development and validation of a scale to measure disease-related symptoms of kidney cancer
David Cella et al.
VALUE IN HEALTH (2007)
Symptom burden among patients with Renal Cell Carcinoma (RCC): content for a symptom index
Gale Harding et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2007)
Estimates of the cancer incidence and mortality in Europe in 2006
J. Ferlay et al.
ANNALS OF ONCOLOGY (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases
Dong Wook Kim et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Pretreatment factors significantly influence quality of life in cancer patients: A radiation therapy oncology group (RTOG) analysis
Benjamin Movsas et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation
D Wild et al.
VALUE IN HEALTH (2005)
Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life?
AGEM de Boer et al.
QUALITY OF LIFE RESEARCH (2004)
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AM O'Farrell et al.
BLOOD (2003)
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
LJ Murray et al.
CLINICAL & EXPERIMENTAL METASTASIS (2003)
Assessing the clinical significance of single items relative to summated scores
JA Sloan et al.
MAYO CLINIC PROCEEDINGS (2002)
EQ-5D: a measure of health status from the EuroQol Group
R Rabin et al.
ANNALS OF MEDICINE (2001)
Share Paper
